Skip to main
ACLX
ACLX logo

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. demonstrates robust growth potential, evidenced by a 32% quarter-over-quarter average increase in Carvykti sales over the past 12 quarters, highlighting the commercial viability of its products. The increasing accessibility of CAR T therapies, as shown by the rise in community physicians capable of dosing from 29% to 47%, suggests a broader adoption and market penetration for their innovative treatments. Furthermore, with projections estimating the BCMA CAR T market expansion from approximately $2.2 billion in 2025 to about $11.5 billion by 2035, Arcellx is well-positioned to capture significant market share, particularly if its lead candidate, anito-cel, receives approval and showcases its differentiated safety profile in future trials.

Bears say

Arcellx faces a challenging outlook due to conservative sales estimates that fall significantly below market consensus, reflecting a projected 2035 sales figure of $11.5 billion for CAR T therapies in multiple myeloma, compared to the $16.5 billion consensus estimate. The company is also susceptible to execution risks within its drug pipeline, compounded by potential regulatory hurdles related to drug pricing, which could exacerbate financial pressures. Additionally, the overall health of the capital markets for biotechnology funding raises concerns about Arcellx’s ability to secure necessary financial support amid a competitive landscape.

Arcellx (ACLX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Arcellx (ACLX) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.